Classes of therapeutics to amplify the immune response.
Yang HuMark E BurkardPublished in: Breast cancer research and treatment (2021)
Mechanistic considerations should inform biomarker development and patient selection for therapeutic combinations of drugs to combine with immune-checkpoint inhibitors.